From: Skinner, Julie M.
To: Bruce Forrest
Subject: RE: Introduction and Invitation
Date: Friday, October 15, 2021 8:39:46 AM

Good morning Bruce,
It's great to hear from you! Thanks for reaching out. We've reviewed the Pogona, LLC PCV IP with our IP counsel and do not have any interest in the IP at this time.
Have a wonderful weekend!
Best Regards,
Julie

From: Bruce Forrest <bruce.forrest@hudsoninnovations.net>
Sent: Sunday, October 10, 2021 11:33 AM
To: Skinner, Julie M. <julie_skinner@merck.com>
Subject: Re: Introduction and Invitation

EXTERNAL EMAIL – Use caution with any links or file attachments.

Dear Julie,

My apologies for reaching out to you directly, but I really enjoyed participating with you, David and your team on the advisory panel for your next generation pneumococcal vaccine program, V116.

More importantly, even without knowing the actual V116 composition, I was impressed that there was one of the large companies giving consideration to finding a composition that actually addressed the population coverage needs rather than continuing to simply embrace the 1970's compositions of Robert Austrian that are now far disconnected from what is actually needed.

As I had declared before, I have been developing IP around next generation PCV compositions.

To that end, I'd like to explore any interest that Merck might have in the IP that my team and I have developed in this field. As you might recall, Merck explored some of this IP back in 2018 where we were looking too develop it in Liffey Biotech Limited. So, it may not be entirely unfamiliar to the firm.

Since then, the IP is now in Pogona, LLC, and we have one patent now granted in August, expecting the allowance of a second patent this year, and we are beginning the process of generating divisional filings etc. to expand on the original applications and PCT filings.

While we have begun the process of raising funds to develop a next generation PCV from this IP, given our team's enormous experience in the development, approval, manufacturing and commercialization of PCV (all being in previously senior level roles at Pfizer/Wyeth for Prevnar and Prevnar 13 previously), we have also recently been contacted by one private firm, another NASDAQ

traded firm, and an attorney representing another yet undisclosed client each with the express interest of exploring our willingness to consider licensing the IP.

It has been a busy few weeks.

This external interest resulted in us giving more serious reconsideration to exploring licensing or partnering opportunities, now that the current generation of PCV have recently been approved by the FDA.

My suspicion is that we have shared interests in a truly novel PCV, and if that is so, we would prefer not to be a hindrance to seeing that come to fruition to our mutual benefit. My preference is for this IP to be with a firm that I know has the wherewithal to see this developed successfully.

I could share a slide set, a two page summary, but since this is about the IP, I have attached the issued patent, and additional patent application numbers for the US, Europe and Japan where applicable.

If there might be some additional interest in exploring any element of this with me, feel free to reach back out.

I am in the NY area, and would be happy to drive and meet at any Merck location. Even informally.

- US Patent Grant: US11058757
    - Priority Date: 03/31/2016
- US Patent Application: 17/347435
- US Patent Application: 16/753597
- Japan Patent Application: 2019-502538
- EP Patent Application: 1776881.9
- EP Patent Application: 18864637.6
- PCT Patent Application PCT/US2018/54391

Kindest Regards,

Bruce

Bruce D Forrest, MD MBA
Manager
Pogona, LLC.

we will leave the details to the folks writing up the agreements.
In the meantime, I have cc'd my colleagues David McIntosh and Christine Gracin who are organizing this event. Christine will be in touch with next steps. Please let me know if you have any additional questions. I look forward to connecting with you at this event!

Best regards,
Julie

From: Bruce Forrest <bruce.forrest@hudsoninnovations.net>
Sent: Wednesday, February 10, 2021 3:25 PM
To: Skinner, Julie M. <julie_skinner@merck.com>
Subject: Re: Introduction and Invitation

EXTERNAL EMAIL – Use caution with any links or file attachments.
Dear Julie,

Thank you for reaching out and for your kind words.

I have been following your efforts for some time. I am sure we have many friends in common.

I'd be delighted to explore participating in this event.

Full disclosure … I do hold patent applications in the field of expanded coverage pneumococcal conjugate vaccines, and in a former existence Merck was involved in due diligence on that IP.

These are owned in an entity with my business partner, Jack Love, who headed Wyeth's vaccines' regulatory affairs organization and secured the regulatory approvals of Prevnar 13, Trumemba, etc. and worked with me previously when I was the global clinical team lead on Prevnar 13.

I hope that this is not a problem. If you want to follow-up please do not hesitate to reach out.

Kindest regards,

Bruce

Bruce D Forrest, MD MBA
President
Hudson Innovations, LLC.

on April 20 and 22 (likely 3-4 hour time block each day, TBD). I attended the AMR COMBINE virtual symposium this week and heard you speak about PCV clinical trials. Given your background and expertise, I would like to extend an invitation to you for this event. If you are interested and available, I can gladly connect you with our event manager to work through the details. Please let me know if you have any questions or would like to chat about this opportunity.

Best regards,
Julie Skinner

Julie M. Skinner, PhD
Senior Principal Scientist
Merck Research Laboratories
Vaccines Early Discovery
770 Sumneytown Pike
WP14-3
West Point, PA 19486-0004
Ph: 215.652.1057
julie_skinner@merck.com

"Everyone you meet is fighting a battle you know nothing about. Be Kind. Always."

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (2000 Galloping Hill Road, Kenilworth, New Jersey, USA 07033), and/or its affiliates Direct contact information for affiliates is available at http://www.merck.com/contact/contacts.html) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (2000 Galloping Hill Road, Kenilworth, New Jersey, USA 07033), and/or its affiliates Direct contact information for affiliates is available at http://www.merck.com/contact/contacts.html) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (2000 Galloping Hill Road, Kenilworth, New Jersey, USA 07033), and/or its affiliates Direct contact information for affiliates is available at http://www.merck.com/contact/contacts.html) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.